NDAORALTABLET
Approved
May 2009
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
7/8 — Comprehensive
CYCLOSET (bromocriptine mesylate) by Aurobindo Pharma is mesylate, a sympatholytic, dopamine d2 receptor agonist. Approved for type 2 diabetes mellitus, type 1 diabetes, diabetic ketoacidosis. First approved in 2009.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CYCLOSET (bromocriptine mesylate) is an oral dopamine D2 receptor agonist approved for type 2 diabetes, type 1 diabetes, and diabetic ketoacidosis. Timed morning dosing increases insulin sensitivity and glucose disposal while reducing fasting and postprandial hyperglycemia without raising plasma insulin levels. It represents a unique dopaminergic approach to glycemic control distinct from conventional diabetes agents.
$3MPart D
Peak6.0 years to LOEModest Part D utilization with 3,358 claims in 2023 suggests a niche product with stable but limited commercial scale, requiring highly specialized medical affairs and focused field team deployment.
Mechanism of Action
mesylate, a sympatholytic, dopamine D2 receptor agonist. In patients with type 2 diabetes, timed morning administration of CYCLOSET is associated with increased insulin sensitivity and glucose disposal and reduced fasting and postprandial hyperglycemia throughout the meals of the day without…
Indications (3)
Worked on CYCLOSET at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.